Variant Bio is a Seattle-based biotech company entering a rapid growth stage having closed a $105mm Series B financing in the fourth quarter of 2021. The company was started because we believe that human genetics has the power to transform drug development. We are working towards developing therapies to improve global health by studying the genes of people who are outliers for medically relevant traits. To facilitate this, we have built proprietary genomics and phenotyping platforms that allow us to dramatically reduce the cost of genomic studies and identify genetically-validated targets for therapeutic development.
Our team of geneticists, medical researchers, biologists and drug hunters continue to advance multiple projects through internal target validation and lead optimization efforts in relentless pursuit of translating human genetic insights into life-saving therapies.
All of our studies are co-designed with local partners: community groups, academics, and hospitals around the world, and we built Variant Bio from the ground up with ethics at its foundation. We recognize the contribution of our partners through an industry leading benefit-sharing program that dedicates 4% of our revenue and equity value to support local healthcare, sustainable development, education, research, and capacity-building initiatives. Through the Affordable Medicines Pledge we acknowledge that the communities who contributed data that led to the discovery of these new drugs have an equal and reciprocal right to share in the benefits, both financial and social.
Variant Bio is an equal opportunity employer that guarantees a work environment that respects and values diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, sex, gender, gender expression, sexual orientation, age, marital status, veteran status, or disability status.